Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes
Verify the seller is reputable
Optimized Fat Metabolism for Leaner Physique: L-carnitine plays a crucial role in the breakdown of stored fat, transforming it into usable energy for your body
L- carnitine can increase the levels of L carnitine levels in people whose natural L-carnitine level is low
A literature review of human studies from 2014 to 2024 examining glutathione therapy in non-alcoholic fatty liver disease (NAFLD) found consistent improvements in alanine transaminase (ALT) levels and reductions in oxidative stress markers in subjects receiving glutathione as the primary intervention
These findings delineate a novel AR-dependent axis crucial for muscle strength, offering potential therapeutic targets for muscle-wasting conditions [42]
